BACKGROUND: The purpose of this study was to determine the effect of a novel epidermal growth factor (EGF) receptor tyrosine kinase inhibitor, Erlotinib, on pancreatic cancer cell lines of varying differentiation in vitro. METHODS: Six pancreatic cancer cell lines (AsPc-1, CAPAN-1, HPAC, HPAF-II, Mia PaCa-2, PANC-1) were grown in the presence of 50 microM or 100 microM of Erlotinib or recombinant EGF. Cell proliferation was determined using the MTT assay over 72 hours. The EGF receptor gene and protein expression were determined by polymerase chain reaction and immunohistochemistry respectively. RESULTS: All cell lines demonstrated the presence of the EGF receptor gene and its gene product. Five of six cell lines showed significant growth inhibition at 72 hours compared with controls (P <0.05). The EGF augmentation increased proliferation of each cell line but this increase was only significant in AsPc-1. CONCLUSIONS: Inhibition of EGF receptor is a valid therapeutic strategy in pancreatic cancer.
BACKGROUND: The purpose of this study was to determine the effect of a novel epidermal growth factor (EGF) receptor tyrosine kinase inhibitor, Erlotinib, on pancreatic cancer cell lines of varying differentiation in vitro. METHODS: Six pancreatic cancer cell lines (AsPc-1, CAPAN-1, HPAC, HPAF-II, Mia PaCa-2, PANC-1) were grown in the presence of 50 microM or 100 microM of Erlotinib or recombinant EGF. Cell proliferation was determined using the MTT assay over 72 hours. The EGF receptor gene and protein expression were determined by polymerase chain reaction and immunohistochemistry respectively. RESULTS: All cell lines demonstrated the presence of the EGF receptor gene and its gene product. Five of six cell lines showed significant growth inhibition at 72 hours compared with controls (P <0.05). The EGF augmentation increased proliferation of each cell line but this increase was only significant in AsPc-1. CONCLUSIONS: Inhibition of EGF receptor is a valid therapeutic strategy in pancreatic cancer.
Authors: Brian W Pogue; Kimberley S Samkoe; Shannon Hextrum; Julia A O'Hara; Michael Jermyn; Subhadra Srinivasan; Tayyaba Hasan Journal: J Biomed Opt Date: 2010 May-Jun Impact factor: 3.170
Authors: Altaf Mohammed; Naveena B Janakiram; Qian Li; Venkateshwar Madka; Misty Ely; Stan Lightfoot; Howard Crawford; Vernon E Steele; Chinthalapally V Rao Journal: Cancer Prev Res (Phila) Date: 2010-11
Authors: Kimberley S Samkoe; Kristian Sexton; Kenneth M Tichauer; Shannon K Hextrum; Omar Pardesi; Scott C Davis; Julia A O'Hara; P Jack Hoopes; Tayyaba Hasan; Brian W Pogue Journal: Mol Imaging Biol Date: 2012-08 Impact factor: 3.488
Authors: Kimberley S Samkoe; Alina Chen; Imran Rizvi; Julia A O'Hara; P Jack Hoopes; Stephen P Pereira; Tayyaba Hasan; Brian W Pogue Journal: Int J Radiat Oncol Biol Phys Date: 2010-01-01 Impact factor: 7.038
Authors: Daniel Borja-Cacho; Eric Hans Jensen; Ashok Kumar Saluja; Donald J Buchsbaum; Selwyn Maurice Vickers Journal: Am J Surg Date: 2008-09 Impact factor: 2.565
Authors: Chinthalapally V Rao; Naveena B Janakiram; Venkateshwar Madka; Vishal Devarkonda; Misty Brewer; Laura Biddick; Stan Lightfoot; Vernon E Steele; Altaf Mohammed Journal: Oncotarget Date: 2015-10-20
Authors: Serena Veschi; Laura De Lellis; Rosalba Florio; Paola Lanuti; Alberto Massucci; Nicola Tinari; Michele De Tursi; Pierluigi di Sebastiano; Marco Marchisio; Clara Natoli; Alessandro Cama Journal: J Exp Clin Cancer Res Date: 2018-09-21